---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021511"
form_type: "8-K"
ticker: "LFST"
cik: "0001845257"
company_name: "LifeStance Health Group, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:29:23.733851+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LifeStance Q4 revenue $280.6M (+22% YoY); net loss $45M; guides FY24 revenue $1.19-$1.24B

## Summary
- Q4 revenue $280.6M (+22% YoY); full-year revenue $1,055.7M (+23%).
- Q4 net loss $45.0M; full-year net loss $186.3M. Adjusted EBITDA $20.3M (Q4) and $59.0M (FY).
- Added 227 net clinicians in Q4, 1,014 in FY; total clinicians 6,645 (+18% YoY).
- FY2024 guidance: revenue $1.19-$1.24B, Center Margin $345-$365M, Adj. EBITDA $80-$90M, positive free cash flow.

## SEC filing metadata
- accession: 0000950170-24-021511
- form_type: 8-K
- ticker: LFST
- cik: 0001845257
- company_name: LifeStance Health Group, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845257/000095017024021511/0000950170-24-021511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845257/000095017024021511/lfst-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021511
- JSON: https://secwatch.observer/filing/0000950170-24-021511.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021511.txt

## Key facts
- Earnings Releases
  LifeStance Health Group, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $280.6 million, net income Net loss of $45.0 million. Guidance initiated.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: $280.6 million
  - Net income: Net loss of $45.0 million
  - Guidance: initiated
  - Result: reported results
  source text: full year ended December 31, 2023. (All results compared to prior-year comparative period, unless otherwise noted) 2023 Highlights and 2024 Outlook • Fourth quarter revenue of $280.6 million increased 22% and full year revenue of $1,055.7 million increased 23% compared to revenue of $859.5 million • Clinician base increased 18% to 6,645 clinicians, including 227 net
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845257/000095017024021511/0000950170-24-021511-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.